(NASDAQ:BLUE) traded lower for the fourth straight session as Bank of America and J.P. Morgan downgraded the gene therapy developer after its Q3 2024 results fell short of expectations for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback